Assess whether RWE can replace or only supplement an RCT (f4c932)

Situation

In an RWE group proposing a post-marketing study instead of a new RCT, CMC comparability package for a site change is the evidence after an AdCom briefing document that overstates subgroup findings. RWE evidence-strategy director has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences Pharmacovigilance close using CMC comparability package for a site change.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• An AdCom briefing document that overstates subgroup findings is noise around an already-controlled Pharmacovigilance process in an RWE group proposing a post-marketing study instead of a new RCT, given CMC comparability package for a site change.
• An AdCom briefing document that overstates subgroup findings is the event in CMC comparability package for a site change that forces RWE can replace for RWE evidence-strategy director under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a Pharmacovigilance program failure.
• CMC comparability package for a site change cannot decide RWE can replace or yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether CMC comparability package for a site change supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against an AdCom briefing document that overstates subgroup findings and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.